DexCom (NASDAQ:DXCM) Surpasses Q4 CY2025 Revenue and EPS Outlooks

DexCom (NASDAQ:DXCM) reported Q4 CY2025 revenue of $1.26B, up 13.1% YoY, and non-GAAP EPS of $0.68, 4.5% above consensus. Organic revenue growth over the past two years averaged 14.1% YoY, core operations drove most of the results, and the operating margin expanded 8.7 pp to 25.6% in Q4. Analysts project full-year 2026 revenue of $5.21B and EPS of $2.09, up 18.4% from 2025. Key context: The company’s five-year CAGR for revenue is 19.3%, EPS is 22.1%, and operating margin is 15.7% (with 8.7 pp expansion over the five-year period and a 4.4% share count reduction). Despite a moderation in two-year growth, strong fundamentals, healthy margins, and consistent EPS expansion suggest continued demand for its continuous glucose monitoring systems.